Trial Profile
Tysabri Outreach: Unified Commitment to Health
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TOUCH
- Sponsors Elan Pharmaceuticals
- 27 Apr 2023 Results of updated analysis (as of June 30, 2022), assessing Progressive Multifocal Leukoencephalopathy (PML) risk with natalizumab EID in comparison with Q4W dosing using TOUCH data , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 26 Apr 2022 Results( as of June 30, 2021) of Updated Analysis of the TOUCH Prescribing Program , presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 19 May 2020 According to a Biogen media release, data from this trial will be available online via the 2020 AAN Science Highlights virtual platform.